Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan

Strategies for Prolonged Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

(2010) Panos Fidias et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer: Results of an Exploratory Subgroup Analysis of a Phase III Trial

(2010) Chih-Hsin Yang et al.   Journal of Thoracic Oncology

Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy

(2010) Giovanni Giuliani et al.   LUNG CANCER

Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany

(2010) Helge G. Bischoff et al.   LUNG CANCER

Limitations on Work and Attendance Rates after Employees with Cancer Returned to Work at a Single Manufacturing Company in Japan

(2009) Takayuki Ohguri et al.   JOURNAL OF OCCUPATIONAL HEALTH

Measuring Outcomes in Palliative Care: Limitations of QALYs and the Road to PalYs

(2009) Charles Normand   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Costs for 5-year lung cancer survivors in a tertiary care hospital in South Korea

(2009) Young Sik Park et al.   LUNG CANCER

Pharmacoeconomic Evaluations in the Treatment of Non-Small Cell Lung Cancer

(2008) Josh J Carlson et al.   DRUGS

Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis

(2008) João Paulo da Silveira Nogueira Lima et al.   EUROPEAN JOURNAL OF CANCER

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Giorgio Vittorio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY